Jay Chhablani1, Rama Jager2,3, Joshua Ong4, Ryan Lohrenz5, Russell J Hamilton6, Baldassare Stea6,7, Mary Drew5, Gregg Kokame8. 1. Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. jay.chhablani@gmail.com. 2. University Retina and Macula Associates, Oak Forest, IL, USA. 3. University of Illinois, Chicago, IL, USA. 4. Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 5. SalutarisMD, Tucson, AZ, USA. 6. Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA. 7. University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA. 8. Division of Ophthalmology, Department of Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA.
Abstract
PURPOSE: This study was designed to demonstrate the safety and feasibility of episcleral brachytherapy (ESB) for the treatment of anti-vascular endothelial growth factor (anti-VEGF) resistant neovascular age-related macular degeneration (nAMD) in a 6-subject cohort adjunct to anti-VEGF therapy. METHODS: Six eyes of six subjects with anti-VEGF resistant nAMD (persistent fluid or hemorrhage despite frequent anti-VEGF treatment) were treated with ESB between May 2018 and July 2018 as part of a larger early feasibility trial. Baseline and follow-up exams with multi-modal imaging were conducted. RESULTS: In this analysis, six eyes were included. The mean age was 74.7 years; 33% were female; 67% had polypoidal choroidal vasculopathy. The mean number of lifetime anti-VEGF injections received prior to the study enrollment was 33.9 injections and 10 injections in the year prior to the study enrollment. In the first and second years following ESB, the mean number of injections was 8.5 and 8, respectively. No evidence of radiation-induced toxicity through 2 years following ESB was observed. The mean baseline VA was 55.3 letters. At 1 year, the mean VA increased by 3.2 letters and 1.7 letters at year 2. At 2 years, the mean change in vascular complex on ICGA was - 18%, - 43% on OCTA, and - 5% on FA. The subjects also experienced a mean decrease in CRT on OCT of 21% after 2 years. CONCLUSIONS: The results from this six-subject cohort with 2-year data support additional investigations of ESB for nAMD, specifically those with persistent disease activity and treatment resistant nAMD.
PURPOSE: This study was designed to demonstrate the safety and feasibility of episcleral brachytherapy (ESB) for the treatment of anti-vascular endothelial growth factor (anti-VEGF) resistant neovascular age-related macular degeneration (nAMD) in a 6-subject cohort adjunct to anti-VEGF therapy. METHODS: Six eyes of six subjects with anti-VEGF resistant nAMD (persistent fluid or hemorrhage despite frequent anti-VEGF treatment) were treated with ESB between May 2018 and July 2018 as part of a larger early feasibility trial. Baseline and follow-up exams with multi-modal imaging were conducted. RESULTS: In this analysis, six eyes were included. The mean age was 74.7 years; 33% were female; 67% had polypoidal choroidal vasculopathy. The mean number of lifetime anti-VEGF injections received prior to the study enrollment was 33.9 injections and 10 injections in the year prior to the study enrollment. In the first and second years following ESB, the mean number of injections was 8.5 and 8, respectively. No evidence of radiation-induced toxicity through 2 years following ESB was observed. The mean baseline VA was 55.3 letters. At 1 year, the mean VA increased by 3.2 letters and 1.7 letters at year 2. At 2 years, the mean change in vascular complex on ICGA was - 18%, - 43% on OCTA, and - 5% on FA. The subjects also experienced a mean decrease in CRT on OCT of 21% after 2 years. CONCLUSIONS: The results from this six-subject cohort with 2-year data support additional investigations of ESB for nAMD, specifically those with persistent disease activity and treatment resistant nAMD.
Authors: Kakarla V Chalam; Sankarathi Balaiya; Robert S Malyappa; Wen Hsi; Vikram S Brar; Ravi K Murthy Journal: Retina Date: 2011-01 Impact factor: 4.256
Authors: Ruwan A Silva; Andrew A Moshfeghi; Peter K Kaiser; Rishi P Singh; Darius M Moshfeghi Journal: Semin Ophthalmol Date: 2011-05 Impact factor: 1.975
Authors: Florian M Heussen; Yanling Ouyang; Srinivas R Sadda; Alexander C Walsh Journal: Invest Ophthalmol Vis Sci Date: 2011-09-29 Impact factor: 4.799
Authors: Camiel J F Boon; Reinier O Schlingemann; Marc J Sirks; Elon H C van Dijk; Noa Rosenberg; Carla E M Hollak; Stamatios Aslanis; Chui Ming Gemmy Cheung; Itay Chowers; Chiara M Eandi; K Bailey Freund; Frank G Holz; Peter K Kaiser; Andrew J Lotery; Kyoko Ohno-Matsui; Giuseppe Querques; Yousif Subhi; Ramin Tadayoni; Charles C Wykoff; Dinah Zur; Roselie M H Diederen Journal: Acta Ophthalmol Date: 2022-04-06 Impact factor: 3.988